Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial
Ellen M. Apperloo(Dialyse Centrum Groningen), Marcel H.A. Muskiet(Amsterdam University Medical Centers), Hiddo J.L. Heerspink(University Medical Center Groningen), Niels Jongs(University Medical Center Groningen), Dennis B. Rouw(Martini Ziekenhuis), Daniël H. van Raalte(Amsterdam University Medical Centers), Klaas Hoogenberg(Martini Ziekenhuis), Annemarie B. van der Aart(Martini Ziekenhuis)
Cited by 3
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990